High-dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity

Pediatric Blood and Cancer

Volumn 44, Issue 3, 2005, Pages 215-219

  Berrak, Su Gülsün ^a   Pearson, Margaret ^b   Berberoǧlu, Semha ^c   Ilhan, Inci Ergürhan ^d   Jaffe, Norman ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b UNIVERSITY OF TEXAS   (United States)

^c ANKARA ONCOLOGY HOSPITAL   (Turkey)

^d SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

High dose ifosfamide; Metastatic; Osteosarcoma; Relapsed

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FEVER; GLUCOSURIA; HEMODIALYSIS; HEMORRHAGIC CYSTITIS; HEPATITIS A; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LUNG TUMOR; MALE; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEINURIA; PSYCHOSIS; SOFT TISSUE TUMOR; SUICIDE ATTEMPT;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; NEOPLASMS, SECOND PRIMARY; OSTEOSARCOMA; RECURRENCE; TREATMENT OUTCOME;

EID: 13444253743     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20228     Document Type: Article

References (36)

1. Link MP, Eilber F. Osteosarcoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott-Raven Publishers; 1997. pp 889-920.
2. Young JL Jr, Miller RW. Incidence of malignant tumors in U. S. children. J Pediatr 1975;86:254-258.
3. Bacci G, Mercuri M, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 1997; 79:245-254.
4. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-1606.
5. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72:3227-3238.
6. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop 1991;270: 8-14.
7. Meyers PA, Heller G, Healey J, et al. Chemotherapy for non-metastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
8. Bacci G, Picci P, Briccoli A, et al. Osteosarcoma of the extremity metastatic at presentation: Results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions). Tumori 1992;78:200-206.
9. Cassano WF, Graham-Pole J, Dickson N. Etoposide, cyclophosphamide, cisplatin, and doxorubicin as neoadjuvant chemotherapy for osteosarcoma. Cancer 1991;68:1899-1902.
10. Goorin AM, Abelson HT, Frei E 3rd. Osteosarcoma: Fifteen years later. N Engl J Med 1985;313:1637-1643.
11. Goorin AM, Delorey MJ, Lack EE, et al. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: Analysis of 32 patients. J Clin Oncol 1984;2:425-431.
12. Huth JF, Eilber FR. Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases. Arch Surg 1989;124:122-126.
13. Parham DM, Pratt CB, Parvey LS, et al. Childhood multifocal osteosarcoma. Clinicopathologic and radiologic correlates. Cancer 1985;55:2653-2658.
14. Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995;75:1084-1093.
15. Solheim OP, Saeter G, Elomaa I, et al. The treatment of osteosarcoma: Present trends. The Scandinavian Sarcoma Group experience. Ann Oncol 1992;3:S7-11.
16. Tabone MD, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994;12:2614-2620.
17. Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 1993;71:1898-1903.
18. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-1198.
19. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol 1997;15:2378-2384.
20. Ayala AG, Raymond AK, Jaffe N. The pathologist's role in the diagnosis and treatment of osteosarcoma in children. Hum Pathol 1984;15:258-266.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
22. Jurgens H, Treuner J, Winkler K, et al. Ifosfamide in pediatric malignancies. Semin Oncol 1989;16:46-50.
23. Voute PA, Souhami RL, Nooij M, et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol 1999;10:1211-1218.
24. Marti C, Kroner T, Remagen W, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 1985;69:115-117.
25. Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 1987;71:131-135.
26. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A Pediatric Oncology Group study. Med Pediatr Oncol 1995; 24:87-92.
27. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study. J Clin Oncol 1998;16:3641-3648.
28. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. J Clin Oncol 2002; 20:426-433.
29. Goorin AM, Gieser P, Ferguson WS, et al. Successful phase II trial of etoposide and high dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group Trial (POG). J Clin Oncol 1998;17:2056 (abstract).
30. Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 1997;33: 232-237.
31. Canpolat C, Pearson P, Robertson R, et al. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: Renal, hematologic, and neurologic observations. Med Pediatr Oncol 1996;26:36-47.
32. Ferrari S, Zolezzi C, Cesari M, et al. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide. Anticancer Drugs 1999;10:25-31.
33. Arndt C, Morgenstern B, Hawkins D, et al. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol 1999; 32:93-96.
34. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994;73:2506-2511.
35. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-1608.
36. Elias AD, Eder JP, Shea T, et al. High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 1990;8:170-178.